Emcure Pharmaceuticals Limited announced its consolidated financial results for the quarter and nine months ended December 31, 2025, on February 04, 2026. The company reported a revenue from operations of ₹2,363 crore for the quarter, marking a 20.4% year-on-year increase. Profit After Tax (PAT) grew by 48.2% to ₹231 crore. EBITDA margins stood at 19.5%, with EBITDA at ₹460 crore, up 27.2% YoY. The domestic business sales were ₹1,025 crore, up 15.4% YoY, driven by strong performance in chronic segments and the launch of Poviztra®, a biological injectable form of semaglutide, in partnership with Novo Nordisk. The international business sales increased by 24.5% to ₹1,338 crore, with all geographies showing strong performance. The Rest of the World (RoW) business grew by 30.7%, and Europe saw strong traction. Canada's business grew by 12.8%. In addition to the financial results, the Board of Directors approved the appointment of Ms. Amruta Jana Yangalwar as the Company Secretary and Compliance Officer. The Board also approved the re-appointment of three Independent Directors: Dr. Shailesh Kripalu Ayyangar for a five-year term from June 02, 2026; Mr. Vijay Keshav Gokhale for a five-year term from April 16, 2026; and Dr. Vidya Rajiv Yeravdekar for a three-year term from April 16, 2026. These re-appointments are subject to shareholder approval. The company will conduct a postal ballot through remote e-voting for these re-appointments. The Board meeting commenced at 12:40 p.m. IST and concluded at 1:15 p.m. IST. The financial results include an exceptional expense of ₹38 crore related to changes in labour codes, effective November 21, 2025, which resulted in a one-time increase in provision for employee benefits.
